Effects of FGFR4 G388R, V10I Polymorphisms on the Likelihood of Cancer

Overview

Journal Sci Rep

Specialty Science

Date 2021 Jan 15

PMID 33446698

Citations 9

Authors

Tao Peng

Yangyang Sun

Zhiwei Lv

Ze Zhang

Quanxin Su

Hao Wu

Wei Zhang

Wei Yuan

Li Zuo

Li Shi

Li-Feng Zhang

Xiaoli Zhou

Yuanyuan Mi

Affiliations

Soon will be listed here.

Abstract

The correlation between G388R or V10I polymorphisms of fibroblast growth factor receptor (FGFR) 4 gene and the risk of carcinoma has been investigated previously, but the results are contradictory. Odds ratios (ORs) with 95% confidence intervals (95%CIs), in silico tools, and immunohistochemical staining (IHS) were adopted to assess the association. In total, 13,793 cancer patients and 16,179 controls were evaluated in our pooled analysis. Summarization of all the studies showed that G388R polymorphism is associated with elevated susceptibility to cancer under homozygous comparison (OR = 1.21, 95%CI = 1.03-1.43, P = 0.020) and a recessive genetic model (OR = 1.21, 95%CI = 1.04-1.41, P = 0.012). In the stratification analysis by cancer type and ethnicity, similar findings were indicated for prostate cancer, breast cancer, and individuals of Asian descendant. Polyphen2 bioinformatics analysis showed that the G388R mutation is predicted to damage the protein function of FGFR4. IHS analysis indicated that FGFR4 expression is increased in advanced prostate cancer. These findings may guide personalized treatment of certain types of cancers. Up-regulation of FGFR4 may be related to a poor prognosis in prostate cancer.

Citing Articles

Predictive significance of FGFR4 p.G388R polymorphism in metastatic colorectal cancer patients receiving trifluridine/tipiracil (TAS-102) treatment.

Ottaiano A, Santorsola M, Ianniello M, Ceccarelli A, Casillo M, Sabbatino F J Transl Med. 2024; 22(1):379.

PMID: 38650006 PMC: 11036552. DOI: 10.1186/s12967-024-05184-w.

HER2-Positive Lacrimal Sac Squamous Cell Carcinoma in a 57-Year-Old Man.

Grachev N, Rabaev G, Avdalyan A, Znamenskiy I, Mosin D, Ustyuzhanin D Case Rep Oncol. 2024; 17(1):142-149.

PMID: 38288459 PMC: 10824523. DOI: 10.1159/000536061.

Bioinformatic Analysis of Recurrent Genomic Alterations and Corresponding Pathway Alterations in Ewing Sarcoma.

Rock A, Uche A, Yoon J, Agulnik M, Chow W, Millis S J Pers Med. 2023; 13(10).

PMID: 37888109 PMC: 10608227. DOI: 10.3390/jpm13101499.

Eosinophils Infiltration in Esophageal Muscularis Propria Induces Achalasia-like Esophageal Motility Disorder in Mice.

Zhao W, Wang B, Zhang L, Jin H Biomolecules. 2022; 12(12).

PMID: 36551293 PMC: 9775547. DOI: 10.3390/biom12121865.

A scientometric analysis of research trends on emerging contaminants in the field of cancer in 2012-2021.

Zheng D, Chen L, Tian H, Yang Q, Wu J, Ji Z Front Public Health. 2022; 10:1034585.

PMID: 36504950 PMC: 9733951. DOI: 10.3389/fpubh.2022.1034585.

References

Sheu M, Hsieh M, Chiang W, Yang S, Lee H, Lee L . Fibroblast growth factor receptor 4 polymorphism is associated with liver cirrhosis in hepatocarcinoma. PLoS One. 2015; 10(4):e0122961. PMC: 4393280. DOI: 10.1371/journal.pone.0122961. View

Wirawati V, Widiati N, Gunawan G, Saragih G, Hening P, Wihadmadyatami H . The distribution of serotonergic nerve on the hippocampus of the fruit bats (). Vet World. 2019; 12(9):1460-1466. PMC: 6813612. DOI: 10.14202/vetworld.2019.1460-1466. View

Dai F, Zhu L, Zhang W, Mi Y, Sun H, Zhang L . The association between three AXIN2 variants and cancer risk. J Cell Biochem. 2019; 120(9):15561-15571. DOI: 10.1002/jcb.28823. View

Tang S, Hao Y, Yuan Y, Liu R, Chen Q . Role of fibroblast growth factor receptor 4 in cancer. Cancer Sci. 2018; 109(10):3024-3031. PMC: 6172014. DOI: 10.1111/cas.13759. View

Zhang L, Xu K, Tang B, Zhang W, Yuan W, Yue C . Association between SOD2 V16A variant and urological cancer risk. Aging (Albany NY). 2020; 12(1):825-843. PMC: 6977677. DOI: 10.18632/aging.102658. View

Powers C, McLeskey S, Wellstein A . Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer. 2000; 7(3):165-97. DOI: 10.1677/erc.0.0070165. View

Gowardhan B, Douglas D, Mathers M, McKie A, McCracken S, Robson C . Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer. 2005; 92(2):320-7. PMC: 2361833. DOI: 10.1038/sj.bjc.6602274. View

Shen Y, Lu Y, Shen D, Liu Y, Su X, Zhu G . Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients. World J Gastroenterol. 2013; 19(28):4568-75. PMC: 3725383. DOI: 10.3748/wjg.v19.i28.4568. View

Chen T, Yang S, Liu Y, Lin W, Han C, Wang P . Association of Fibroblast Growth Factor Receptor 4 Genetic Polymorphisms With the Development of Uterine Cervical Cancer and Patient Prognosis. Reprod Sci. 2017; 25(1):86-93. DOI: 10.1177/1933719117702250. View

10.

Morimoto Y, Ozaki T, Ouchida M, Umehara N, Ohata N, Yoshida A . Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer. 2003; 98(10):2245-50. DOI: 10.1002/cncr.11778. View

11.

Zhu L, Wang J, Yue C, Yuan W, Zhang W, Shi L . CDKN1B Val 109 Gly variant is not related to risk of prostate cancer. J Cell Biochem. 2019; 120(10):18346-18356. DOI: 10.1002/jcb.29144. View

12.

Batschauer A, Cruz N, Oliveira V, Coelho F, Santos I, Alves M . HFE, MTHFR, and FGFR4 genes polymorphisms and breast cancer in Brazilian women. Mol Cell Biochem. 2011; 357(1-2):247-53. DOI: 10.1007/s11010-011-0895-1. View

13.

Wang J, Stockton D, Ittmann M . The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res. 2004; 10(18 Pt 1):6169-78. DOI: 10.1158/1078-0432.CCR-04-0408. View

14.

Wei W, You Z, Sun S, Wang Y, Zhang X, Pang D . Prognostic implications of fibroblast growth factor receptor 4 polymorphisms in primary breast cancer. Mol Carcinog. 2018; 57(8):988-996. DOI: 10.1002/mc.22819. View

15.

Li Y, Zhang L, Zou Y, Yu Y . Association between FGFR4 gene polymorphism and high-risk HPV infection cervical cancer. Asian Pac J Trop Med. 2017; 10(7):680-684. DOI: 10.1016/j.apjtm.2017.07.008. View

16.

Ho H, Pok S, Streit S, Ruhe J, Hart S, Lim K . Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol. 2008; 50(1):118-27. DOI: 10.1016/j.jhep.2008.08.015. View

17.

Xiong S, Ma J, Feng F, Fu W, Shu S, Ma T . Functional FGFR4 Gly388Arg polymorphism contributes to cancer susceptibility: Evidence from meta-analysis. Oncotarget. 2017; 8(15):25300-25309. PMC: 5421931. DOI: 10.18632/oncotarget.15811. View

18.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

19.

Stanchev S, Stamenov N, Kirkov V, Dzhambazova E, Nikolov D, Paloff A . Differential collagen expression in kidney and heart during hypertension. Bratisl Lek Listy. 2020; 121(1):73-78. DOI: 10.4149/BLL_2020_011. View

20.

Spinola M, Leoni V, Pignatiello C, Conti B, Ravagnani F, Pastorino U . Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol. 2005; 23(29):7307-11. DOI: 10.1200/JCO.2005.17.350. View